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Summary
Objective: Collagenase-3, a matrix metalloproteinase (MMP-13) that can degrade collagen II and aggrecan, is produced by osteoarthritic
(OA) chondrocytes and may contribute to matrix destruction in this disease. Our laboratory has previously identified a specific endocytotic
receptor for collagenase-3 on osteoblastic and fibroblastic cells, which couples with the low-density lipoprotein receptor-related protein
(LRP1) to mediate the internalization and degradation of this enzyme. We hypothesized that the activity of this receptor system is reduced
in OA chondrocytes which may lead to increased local extracellular levels of collagenase-3 and increased destruction of the cartilage matrix
at pericellular sites.
Methods: Human chondrocytes and synoviocytes were obtained from OA knees at the time of joint replacement surgery and from
non-arthritic control specimens following autopsy or surgery. Enzyme-linked immunosorbant assay (ELISA) was used to measure
collagenase-3 secreted from primary cultures. Iodinated collagenase-3 was used to analyze the cell-surface binding, internalization and
intracellular degradation of collagenase-3. Reverse-transcriptase polymerase chain reaction was used to confirm chondrocyte phenotype
and the expression of collagenase-3 and LRP1 mRNAs.
Results: OA chondrocytes and synoviocytes demonstrated significantly reduced (75–77%) binding of recombinant 125I collagenase-3.
Internalization and degradation of the ligand was also significantly reduced (64–72%) in OA cells. Collagenase-3 removal was inhibited by
the LRP1 receptor-associated protein (RAP).
Conclusion: These results suggest a mechanism whereby impaired receptor-mediated removal of collagenase-3 in OA chondrocytes may
lead to enhanced local degradation of the cartilage matrix. This work also implicates an LRP family member in endocytotic receptor-mediated
collagenase-3 processing and suggests a novel therapeutic target for OA.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Introduction
Osteoarthritis (OA), the most common form of arthritis, is
a slowly progressive degeneration of articular cartilage,
particularly of the weight-bearing joints (knee and hip).
An estimated 12% of American adults have clinical
signs of OA1, and the prevalence of symptomatic disease
approaches 85% by age 752. OA is characterized radiologi-
cally by narrowing of the joint space, due initially to loss of
articular cartilage, increased bone density at the involved
joint (secondary to subchondral sclerosis), and osteophyte
development3. At present, there is no curative treatment
for OA, and supportive measures and joint replacement
surgery are the primary options4.
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Though the pathogenesis of OA is multifactorial2, a
common endpoint of the disease is destruction of articular
cartilage. Mounting evidence suggests that a pathophysio-
logical catalyst for OA is a disruption of the normal balance
of cartilage synthesis and degradation5. Type II collagen
and aggrecan, the principal structural components of carti-
lage6, are eroded in OA7,8. As OA chondrocytes have a
limited regenerative capacity, the resulting compromise of
the matrix leads to irreversible cartilage destruction9,10.
Matrix metalloproteinases (MMPs) are enzymes involved
in extracellular matrix remodeling during development,
wound healing, and disease [reviewed in reference 11]. In
OA, degradation of cartilage-specific type II collagen corre-
lates with MMP activity12,13, and MMPs may be detected in
synovial fluids from OA patients, although at lower levels
than in RA patients14–17. The presence of tissue inhibitors
of MMPs (TIMPs) in OA synovial fluids has been proposed
as an endogenous adaptive response to MMP activation,
although a local imbalance in the MMP/TIMP content in OA
cartilage is thought to contribute to progressive matrix
degradation over time18,19. MMP-13, also known as
collagenase-3, acts at physiological pH to degrade fibrillar
native collagens (types I, II, and III) and aggrecan20.
Collagen cleavage occurs at an internal helical site, yield-
ing 1/4 and 3/4 fragments21, and at an aminotelopeptide
site (which may initiate fibrillar depolymerization22,23).
MMP-13 is overexpressed by chondrocytes in OA
cartilage24–26 and type II collagen is the preferred substrate
for MMP-1327. Recent studies using synthetic collagenase
inhibitors have provided evidence that MMP-13 is the major
collagenase involved in chondrocyte-mediated cleavage of
type II collagen28. Furthermore, targeted expression of
constitutively active MMP-13 generates OA-like pathology
in transgenic mice29.
MMP-13 is secreted as a proenzyme, with activation
through autocatalysis, by other MMPs, or by other pro-
teases [reviewed in reference 30]. Activated MMP-13 acts
in the local extracellular milieu prior to proteolytic inactiva-
tion, inhibition by tissue inhibitors of metalloproteinases
(TIMPs)31,32 or receptor-mediated endocytosis and degra-
dation33. A synthetic inhibitor of MMP-13 has been shown
to reduce pathological changes in an experimental model
of OA34, but the endogenous receptor-dependent removal
mechanism for collagenase-3, in the context of OA, has not
been investigated previously. Recent studies showing
close correspondence between distribution of MMP-13
and collagen damage indicate that this enzyme acts
locally to initiate cleavage and denaturation of type II colla-
gen at pericellular and superficial sites in the articular
cartilage35–37. Thus, defective removal of MMP-13 may
contribute to the persistence of active enzyme at these sites.
Our laboratory has previously described a specific endo-
cytotic receptor for collagenase-3 on osteoblastic and
fibroblastic cells. After binding to this receptor,
collagenase-3 is internalized, processed, and excreted
from the cell in degraded form38. Internalization of
collagenase-3 in these cells requires the participation of the
low-density lipoprotein receptor-related protein (LRP1) and
a currently unknown 170 kDa receptor specific to
collagenase-339. We hypothesized that impairment of the
collagenase-3 receptor system contributes to increased
local extracellular levels of collagenase-3 at pericellular
sites, resulting in degeneration of the articular surfaces. We
obtained and cultured human chondrocytes and synovial
cells from OA and non-arthritic individuals and found that
the function of the collagenase-3 receptor system is indeed
impaired in cells derived from OA tissues.
Materials and methods
MATERIALS
Tissue culture media and reagents were purchased from
Fisher Scientific Co. Na125I was obtained from Amersham.
UMR 106-01 rat osteosarcoma cells have been described
previously40. Econopac desalting columns and SDS-PAGE
materials were purchased from BioRad. HiTrap columns for
purification of recombinant proteins were purchased from
Pharmacia. MMPs-1, -2, -9 were a gift from Dr Howard
Welgus. MMP-3 was a gift from Dr Paul Cannon. Purified
rat uterine collagenase-3 was isolated from the media of
cultures of post-partum rat uterine smooth muscle cells as
previously described and provided by Dr John Jeffery41.
The collagenase antibody used was an antiserum raised in
rabbits against purified rat osteosarcoma procollagenase.
The pGEX-receptor-associated protein (RAP) expression
construct was a gift from Dr Joachim Herz (University of
Texas Southwestern Medical Center, Dallas, TX). Other
reagents were purchased from Sigma Chemical Co. or
from Fisher Scientific Co. unless otherwise stated.
PATIENTS
Classification of patients as OA was based upon criteria
established by the American College of Rheumatology4. All
patients in the experimental group showed clinical and
radiographic evidence of OA and were undergoing primary
total knee or hip arthroplasty. All patients in the control
group had no previous history of arthritis or joint trauma
at the site. No evidence of arthritis was observed in the
control tissues at collection. Informed consent was
obtained from all donors. Patients with systemic infection,
autoimmune disease, previous joint surgery or joint trauma
were excluded from the study, as were patients treated with
corticosteroids, bisphosphonates, or intraarticular hyaluro-
nan. Among included patients, there was no significant
difference in mean age or body mass index between the
control and OA groups.
HUMAN TISSUE PREPARATION
Human tissue (articular cartilage and synovium) was
obtained at the time of surgery or within 24 h of autopsy
and was prepared as previously described42, with modifi-
cation. Tissue was minced in a laminar flow hood, then
incubated in sterile-filtered serum-free DMEM (50 ml) con-
taining trypsin (0.25%) for 1 h at 37°C on an orbital shaker.
Tissues were then centrifuged at 2000 rpm for 10 min at
4°C, rinsed in DMEM, and incubated in sterile-filtered
DMEM containing 10% heat-inactivated fetal bovine serum
(FBS; 10% DMEM) and bacterial collagenase (Sigma;
0.7 mg/ml) at 37°C on an orbital shaker for 4 h (synovial
fibroblasts) or overnight (cartilage). Undigested tissue was
removed, and the cells were centrifuged as above then
rinsed and resuspended in 10% DMEM. Cells were
enumerated with a hemocytometer and plated at 5
104 cells/well of 24-well plates (for binding and degradation
assays), or at 4–5106 cells per 75 cm2 flask (for RNA
collection); the cells were plated in proportion to the surface
area to yield similar culture densities in each case. The
culture medium (DMEM plus 10% FBS) was changed thrice
weekly until confluency was reached (typically 3–5 weeks),
at which time experimentation or RNA collection was
performed.
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PRODUCTION OF RECOMBINANT PROTEINS
Recombinant mouse collagenase-3 (which has 87%
amino acid sequence homology with human collagenase-
343) was subcloned into the pET30 expression plasmid
(Stratagene, La Jolla, CA) using restriction endonucleases
(NcoI and BamHI) which flank the cDNA sequence, then
transformed into BL21 Escherichia coli cells. Expression
of recombinant collagenase-3 was induced with the
addition of isopropyl -D-thiogalactoside (IPTG; 0.4 mM,
Boehringer-Mannheim) to a culture in log-phase growth.
After 4 h, cells were centrifuged, and the pellet was washed
in 50 mM Tris buffer (containing 5 mM CaCl2 and 200 mM
NaCl, pH 7.6) and stored overnight at −20°C. The bacterial
pellet was then resuspended (1 ml per 25 ml culture broth)
in PBS containing 6 M guanidine HCl (pH 7.6, lysis buffer).
The lysate was passed through an 18 g needle 8–10× and
was then centrifuged (18 000 rpm at 4°C for 30 min). All
subsequent steps were performed at 4°C. Purification of
protein was performed using a HiTrap nickel column
according to the manufacturer’s protocol, sequentially
washing the column with lysis buffer containing 10 and
40 mM imidazole prior to elution in lysis buffer containing
500 mM imidazole. Refolding and dialysis of purified
collagenase-3 was performed as described previously44,
and the protein was immediately frozen at −70°C. Purified
His-tagged collagenase-3 is enzymatically active (as
determined by gelatin zymography) and has molecular
mass of 58 kDa. Collagenase-3 was labeled with 125I by
the chloramine T method45; the radiolabeled product
retains full enzymatic activity. Purification of the
GST-tagged RAP protein was performed as previously
described46.
RT-PCR ANALYSIS
Total RNA from human cells was isolated using a Tri-
reagent (Sigma). Reverse-transcriptase polymerase chain
reaction (RT-PCR) was performed to detect marker tran-
scripts (collagen types I, II, and aggrecan) as well as
collagenase-3. Reverse transcription was carried out at
42°C for 60 min in the presence of patient RNA (100 ng)
and forward- and reverse-orientation primers to each gene
of interest. The primers were synthesized according to
published sequences47–49 (with modification) as follows.
Collagen 1(I), forward (5′-GCG GAA TTC CCC CAG CCA
CAA AGA GTC-3′); collagen 1(I), reverse (5′-CAG TGC
CAT CGT CAT CGC ACA ACA CCT-3′), Tm79C, ampli-
fies 261 bp fragment. Collagen 1(II), forward (5′-GTC
CCC GTG GCC TCC CCG-3′); collagen 1(II), reverse(5′-CAG TGC CAT CCA CGA GCA CCA GCA CTT-3′),
Tm62C, amplifies 307 bp fragment. Aggrecan, forward(5′-CCA TGC AAT ITG AGA ACT-3′); aggrecan, reverse
(5′-CAG TGC CAT ACA AGA AGA GGA CAC CGT-3′),
Tm50C, amplifies 297 bp fragment. Collagenase-3,
forward (5′-CCT CCT GGG CCA AAT TAT GGA G-3′);
collagenase-3, reverse (5′-CAG CTC CGC ATC AAC CTG
CTG-3′), Tm64C, amplifies 392 bp fragment. LRP1, for-
ward (5′-AAA TGA CAC CAT CTA CTG GGT G-3′);
LRP1, reverse (5′-AGC TGA TGC TGA CGT TGA CCA-3′),
Tm60C, amplifies 361 bp fragment. -actin (purchased
from Stratagene, Menasha, WI), forward (5′-TGA CGG
GGT CAC CCA CAC TGT GCC CAT CTA-3′); -actin,
reverse (5′-CTA GAA GCA TTT GCG GTG GAC GAT GGA
GGG-3′), Tm60C, amplifies 661 bp fragment.
ENZYME-LINKED IMMUNOSORBANT ASSAY (ELISA)
An indirect ELISA was performed on media overlying
human cells. Media (overlying confluent cells ∼96 h) were
collected; 1 M Tris–HCl buffer, pH 7.4, was added to bring
the final concentration to 100 mM Tris–HCl, and the result-
ant solution was stored at −20°C. Purified active rat uterine
collagenase-3 (a mixture of pro- and active enzyme 25 ng
in 0.1 ml borate buffer, pH 8.2) was coated on the wells of
a 96-well microtiter plate and incubated at 4°C overnight to
allow enzyme binding. Samples were thawed on ice, cen-
trifuged to remove cellular debris, and serially diluted.
Polyclonal primary collagenase-3 antibody (1:5000) was
added to dilutions of samples (0.1 ml), and the mixture was
incubated for 1 h at 37°C and overnight at 4°C. The
antibody, prepared and purified from New Zealand white
rabbits against rat collagenase-3 secreted from PTH-
treated UMR 106-01 cells, is highly specific recognizing
only collagenase-3 in the pro- or activated state50 including
from human and mouse (data not shown). The mixture was
centrifuged and the supernatant (0.1 ml) was applied to the
wells (after removing coating solution and rinsing wells with
PBS/Tween-20), and the plate was incubated at 37°C for
45 min. The plate was washed with PBS/Tween-20, then
goat anti-rabbit IgG (Sigma) was added. After 1 h incu-
bation at 37°C, the plate was washed and substrate
solution (p-nitrophenol phosphate in 10% diethanolamine)
was added. After 30 min at 37°C, the plate was read at
405 nm on a model EL311 Microplate Autoreader (BioTek
Instruments, Inc., Winooski, VT).
BINDING ASSAYS
Binding was performed on confluent human cells in
24-well (1.0 cm2) plates as previously described38. Two
hours prior to assay, the media were changed and replaced
with media containing BSA (1 mg/ml) to reduce nonspecific
binding. The cells were then moved to 4°C for 1 h to allow
dissociation of endogenous collagenase-3. Media were
aspirated and changed to BSA-free media, and the cells
were then incubated with varying concentrations (1–20 nM)
of 125I collagenase-3 at 4°C for 2 h on a rocker platform.
Nonspecific binding was accounted for by adding a 200-
fold excess of unlabeled, active recombinant collagenase-3
to replicate wells. After binding, the cells were rinsed 3×
in MEM, lysed with 1 M NaOH, and the lysates were
assessed for radioactivity. Cell enumeration was performed
with a hemocytometer on replicate wells at the end of the
culture period to determine cell numbers.
INTERNALIZATION AND DEGRADATION ASSAYS
These assays were performed as described pre-
viously38, with modification. After binding 125I
collagenase-3 as above (3 nM per well), the cells were
rinsed 3× with cold MEM. Warm (37°C) MEM (250 µl) was
added, and the cells were placed at 37°C for selected
intervals to allow receptor-mediated endocytosis and intra-
cellular processing of the ligand. In experiments measuring
collagenase-3 internalization, cells were incubated at 37°C
for 20 min (the optimum internalization interval) prior to
treatment with 0.25% pronase E (which strips cell-surface
proteins) for 20 min. The cells were then centrifuged to
separate the cell-surface fraction (supernatant) from the
internalized fraction (pellet), and both fractions were
assessed for radioactivity. In experiments measuring
collagenase-3 degradation, media overlying cells were
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collected at specified time points (0, 15, 30, 60, and
90 min). Supernatants (250 µl) were incubated with 20%
trichloroacetic acid (TCA) in ethanol (250 µl) and 2% BSA
in Tris buffer (pH 7.5, 1 ml) for 2 h on a rocking platform to
precipitate intact proteins. Thereafter, supernatants were
centrifuged and the radioactivity in the supernatant was
measured. In some experiments, cells were co-incubated
with the LRP1 RAP (300 nmol) during the binding period.
STATISTICAL ANALYSIS
Statistical comparisons between control and experimen-
tal groups were performed using Student’s t-test or ANOVA
on the SigmaStat program. Receptor kinetics were deter-
mined by nonlinear regression using the GraphPad InPlot
4.0 program. P<0.05 was considered to be statistically
significant.
Results
ANALYSIS OF COLLAGENASE-3 SECRETED BY CULTURED
CHONDROCYTES AND SYNOVIOCYTES
We obtained articular cartilage and synovium from
the knee or hip joints of 17 OA patients and nine
non-arthritic controls (Table I). Primary cultures were
established and analyses were performed once the cells
had reached confluence. Indirect ELISA for collagenase-3
was performed on the media collected from cultures of
articular chondrocytes or synovial fibroblasts (Fig. 1).
Collagenase-3 levels were increased approximately two-
fold in OA compared to control chondrocyte cultures, al-
though the difference was not statistically significant. The
levels of the enzyme were significantly elevated in the
synoviocytes from OA patients (P<0.02). Our results sup-
port the findings from other laboratories25,26 in that higher
constitutive levels were detected in OA than in non-arthritic
chondrocytes even after isolation from the cartilage and
several weeks of culture. The elevated levels of MMP-13
detectable in OA synovial fibroblasts, however, were sur-
prising, since early reports did not detect MMP-13 mRNA in
late primary cultures of these cells in the absence of
cytokine stimulation25.
Analysis of cartilage-specific collagen 1(II) mRNAs con-
firmed the phenotype of both OA and non-OA chondro-
cytes, although aggrecan mRNA was undetectable in some
of these samples, which had been cultured for 3 weeks or
longer (Fig. 2). Inappropriate synthesis of type I collagen by
OA chondrocytes has been noted previously51. However,
MMP-13 mRNA levels were not dramatically elevated in
OA chondrocytes, although one control sample in the
group analyzed expressed no detectable transcript. These
results suggest that there are additional points of post-
transcriptional or post-translational control that determine
the levels of MMP-13 protein secreted by chondrocytes.
DECREASED BINDING OF 125I COLLAGENASE-3 TO OA
CHONDROCYTES AND SYNOVIOCYTES
To investigate the ability of human chondrocytes and
synoviocytes to immobilize collagenase-3 at cell-surface
receptors, we performed binding assays with 125I
collagenase-3 (Fig. 3). Compared to the specific binding
in non-arthritic tissues, OA tissues showed significantly
reduced levels of 125I collagenase-3 specific binding, with a
Table I
Patient and control characteristics
Subject Age Gender Procedure BMI*
Osteoarthritic
1 61 F R knee (TKA)* 29.3
2 67 F L hip (THA) 26.8
3 85 F L hip (THA) 26.8
4 77 M L hip (THA) 29.9
5 78 F R knee (TKA) 26.7
6 55 F L knee (TKA) 27.3
7 59 M R hip (THA) 25.7
8 76 F R knee (TKA) 33.7
9 58 F R hip (THA) 58.4
10 61 F R knee (TKA) 38.1
11 49 F R knee (TKA) 31.7
12 77 F L hip (THA) 34.3
13 54 M R hip (THA) 29.8
14 78 F L knee (TKA) 27.5
15 75 M R knee (TKA) 28.0
16 62 F L hip (THA) 30.1
17 77 M L knee (TKA) 24.8
AVG† 67±11 5 M, 12 F 8 Hip, 9 knee 31.1±7.8
Control
A 60 M R knee (amp) 21.4
B 64 M L knee (hp) 25.9
C 75 F L hip (itf) 27.8
D 25 F R knee (aut) 47.6
E 53 M R hip (amp) 27.0
F 67 F L hip (amp) 23.5
G 62 M L knee (aut) 28.2
H 65 M L knee (aut) 29.7
I 66 M R knee (aut) 27.0
AVG† 60±14 6 M, 3 F 3 Hip, 6 knee 28.7±7.5
*Abbreviations: BMI, body mass index (=weight (kg)/height
(cm2)); R, right; L, left; THA, total hip arthroplasty; TKA, total knee
arthroplasty; amp, amputation; hp, hemipelvectomy (secondary to
metastatic small cell carcinoma); itf, intertrochanteric fracture; aut,
autopsy.
†Ages and BMI are presented as means±SD.
Fig. 1. Analysis of collagenase-3 secreted by cultured human
chondrocytes and synoviocytes. Primary cultures were grown to
confluence and culture supernatants were collected. Indirect
ELISA was performed as described in Materials and Methods
using an antibody against collagenase-3. Results are shown as
mean values±S.E.M. for 44 duplicate samples (17 OA chondrocyte,
nine control chondrocyte, 13 OA synoviocyte, five control synovio-
cyte). Differences between OA and control synoviocytes are
significant (P<0.02 by Student’s t-test).
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76% decrease in OA chondrocytes and a 75.5% decrease
in OA synoviocytes (determined by integrating the area
under the curves). Differences between non-arthritic and
OA cells were statistically significant (P<0.001 by ANOVA,
Dunnett’s post hoc test) for chondrocytes (all data points)
and for synoviocytes (3–20 nM data points). Nonspecific
binding determined by an addition of a 200-fold excess of
unlabeled active recombinant collagenase-3 to replicate
wells was 0–30 fmol/106 cells at all concentrations tested
and was subtracted from the total binding to give specific
binding.
Nonlinear regression analyses of these data support the
presence of two receptor populations, which we have
proposed as the 170 kDa specific collagenase-3 receptor
and the LRP139. These studies further indicate that
decreased binding in OA cells is due to decreased receptor
number rather than an alteration in receptor affinity, as the
Bmax is reduced up to 20-fold (P<0.001 for chondrocytes,
P<0.015 for synoviocytes) without significant change in Kd.
The receptor numbers calculated for a two receptor model
indicate 400–700 000 high-affinity sites on control cells
which are reduced to between 21 and 35 000 sites in cells
from OA patients. Similarly, there are 3.1–4106 low affinity
sites in control cells that are reduced to 0.4–0.6106 sites
on cells of OA patients. These results suggest that the
decreased function of the collagenase-3 receptor in OA
chondrocytes may contribute to the high local levels of this
enzyme reported to co-localize with areas of collagen
damage in OA cartilage26,27.
In osteoblastic cells, the collagenase-3 removal sys-
tem is entirely specific for collagenase-3. To test receptor
specificity in human chondrocytes, a binding competition
was performed using 3 nM 125I collagenase-3 as ligand and
a variety of unlabeled MMPs (300 nM) as competitors
(Fig. 4). While collagenase-3 (MMP-13) was the most
efficient competitor (68.8% decrease in 125I collagenase-3
binding), collagenase-1 (MMP-1) and stromelysin-1
(MMP-3) also competed significantly for binding (a 45.6
and 41.8% reduction, respectively), indicating that these
ligands are also recognized by this receptor system. In
contrast, the gelatinases, MMP-2 (72 kDa) and MMP-9
(92 kDa) did not compete for binding. Similar results
were observed using a higher concentration (15 nM) of
125I collagenase-3 (data not shown).
INTERNALIZATION OF 125I COLLAGENASE-3 AND EFFECTS OF
39 kDa RAP
To determine whether the decreased collagenase-3 bind-
ing in OA tissues correlated with reduced receptor function,
we measured the quantity of 125I collagenase internalized
by OA and control chondrocytes (Fig. 5). We observed a
66% decrease in collagenase-3 internalization in OA cells
compared to control cells (P<0.001). This correlates well
with the binding data above. In other work, we have shown
that internalization of collagenase-3 requires the partici-
pation of the LRP139. As such, we also performed internal-
ization assays in the presence of the 39 kDa LRP RAP, an
intracellular chaperone that prevents ligand interactions
with nascent LRP1; recombinant RAP is a receptor
antagonist which inhibits the endocytosis of all known LRP
ligands52. Collagenase-3 internalization was inhibited by
88% (P<0.001) in control chondrocytes in the presence of
RAP, suggesting that the LRP1 (or other LDL receptor
family member) is involved in collagenase-3 internalization
in human chondrocytes. Incubation of OA chondrocytes
with RAP also reduced collagenase-3 internalization, by
74% (P<0.001). Results with synoviocytes were similar
(data not shown). To explore the possibility that the
changes in the capacity of OA chondrocytes to internalize
MMP-13 is due to altered expression of LRP1, RT-PCR
was performed on RNA from control and OA chondrocytes.
No significant difference in LRP1 expression was seen
between the control and OA chondrocytes when total RNA
was examined by this method (Fig. 6).
RELEASE OF DEGRADED 125I COLLAGENASE-3 IN OA AND
CONTROL HUMAN TISSUES
As receptor-mediated processing of collagenase-3
culminates in extracellular release of degraded ligand, we
next performed binding and internalization assays as
above and measured the presence of degraded (TCA-
soluble) 125I-collagenase-3 in the media overlying cells
(Fig. 7). Compared to non-arthritic tissues, OA chondro-
cytes and synoviocytes demonstrated significantly reduced
(P<0.001 for the 15–90 min data points) release of 125I
collagenase-3, by a proportion of 69 and 71%, respectively
(determined by integrating the area under each curve).
Release of collagenase-3 from these cells was also inhib-
ited by RAP (data not shown). These findings indicate that
processing of collagenase-3 is impaired in OA, likely as a
direct consequence of the impaired binding activity.
Discussion
In this report, we have presented evidence for dysfunc-
tion of the collagenase-3 receptor system in human OA
Fig. 2. RT-PCR analysis of total RNAs expressed by primary
cultures of OA and normal chondrocytes. Total RNA was
obtained from chondrocytes in primary culture for 3–5 weeks, and
RT-PCR was performed as described in Materials and Methods
using 100 ng of RNA and primers specific for 1(I) pro-
collagen (Coll1(I)), aggrecan, 1(II) procollagen (Coll1(II)),
collagenase-3, and -actin. Representative results from OA and
normal control samples are shown.
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tissues. Since collagenase-3 is localized at sites of matrix
degradation in OA cartilage and thus implicated in the
progression of OA, we hypothesized that receptor-
mediated removal of this enzyme was impaired in OA
chondrocytes. Our data indicate that specific binding of
collagenase-3 is drastically reduced in OA tissues. The
observed decrease in collagenase-3 binding compared with
non-arthritic tissues is paralleled by proportionate decreases
in internalization and degradation of the enzyme. These
data suggest a pathophysiological model for the develop-
ment and progression of OA, whereby a primary or second-
ary dysfunction of the collagenase-3 receptor system leads
to increased local levels of this destructive enzyme in the
articular cartilage and its consequent erosion. The role of
impaired function of this system in the OA synovium is less
clear, since the levels of collagenase-3 are lower in OA
synovial fluids than in RA joints, where the degradation of
cartilage occurs largely due to collagenase-3 derived from
the inflamed synovial pannus.
We initially identified the receptor-dependent
collagenase-3 removal activity in the rat osteoblastic osteo-
sarcoma cell line, UMR 106-0133, and have since noted
a similar activity in normal rat osteoblasts and mouse
embryonic fibroblasts38,39, and a human chondrosarcoma
cell line (unpublished observations), as well as in the
human chondrocytes and synovial fibroblasts described
here. Recent work described elsewhere has shown that
collagenase-3 inactivation occurs through a two receptor
mechanism, involving a 170 kDa collagenase-3 receptor as
a high-affinity initial binding receptor and the LRP1 as a
secondary, internalizing receptor39. As described above,
the 39-kDa RAP inhibits the internalization of a wide
variety of ligands bound by LDL receptor superfamily
members52. RAP inhibits internalization of collagenase-3
in rat osteosarcoma cells, normal rat osteoblasts, and
rat embryo fibroblasts38. We have shown here that RAP
also reduces collagenase-3 internalization in human
chondrocytes.
Fig. 3. Decreased binding of 125I collagenase-3 to osteoarthritic chondrocytes and synoviocytes. Binding assays on primary culture cells
were performed at 4°C as described in Materials and Methods. Pooled results, from 26 experiments for chondrocytes (17 OA patients and
nine controls) and 18 experiments for synoviocytes (13 OA patients and five controls), depict mean specific binding (total binding−nonspecific
binding)±S.E.M. for each concentration of 125I collagenase-3 added. Receptor kinetics for two receptor populations (putatively the 170 kDa
collagenase-3 receptor and the LRP1, respectively) are as follows (Bmax±S.E.M. in fmol/106 cells, Kd±S.E.M. in nM). Control chondrocytes:
Bmax1909203, Bmax25940910, Kd113.75.3, Kd210119; OA chondrocytes: Bmax145.510.8, Bmax2739179, Kd18.92.6,
Kd212524; control synoviocytes: Bmax11020180, Bmax260802220, Kd18.62.2, Kd210238; OA synoviocytes: Bmax118859,
Bmax21880610, Kd19.23.0, Kd211227.
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In arthritis, components of the collagenase receptor
system may be subject to reduced expression, due to
multifactorial causes. Our investigations here indicate that
there is no change in expression of LRP1 at the RNA level,
however, it is still possible there are changes in the cell-
surface expression of the protein or a reduction in activity
of the LRP1. Altered expression or function of the yet
unidentified specific collagenase-3 receptor may be
responsible for the functional changes in internalization of
collagenase-3 identified in OA chondrocytes. Alternatively,
local factors in the arthritic joint space may lead to reduced
or dysregulated receptor expression, and genetic variations
may predispose to slowly progressive receptor dysfunction.
While the 170 kDa receptor is completely specific for
collagenase-3 in rodent cells, our work here indicates that
other MMPs, including collagenase-1 (MMP-1) and
stromelysin-1 (MMP-3), are bound by the receptor system
in human cartilaginous tissues. As these enzymes are
elevated in OA, dysfunction of this receptor-mediated
removal system may compound the enzymatic insult to
arthritic tissues.
Some laboratories have reported altered expression of
TIMPs in OA joint tissues that could result in an imbalanced
ratio of MMPs to TIMPs14,18,19. However, the levels of
TIMP-1 and -2 relative to the MMPs in OA synovial fluids do
not reflect the imbalance observed in OA cartilage16.
Rather, it has been proposed that collagenase cleavage
products that result from degradation and denaturation of
type II collagen in the cartilage are more accurate OA
biomarkers than the MMPs themselves when analyzed in
synovial fluids and sera53. Our unpublished data indicate
that binding and internalization of collagenase-3 occur in
either the presence or absence of TIMPs, suggesting that
this receptor system may have the capacity to indepen-
dently regulate extracellular levels of the enzyme at peri-
cellular sites within the cartilage where OA pathology
occurs. In OA cartilage, collagen degradation occurs
initially in the superficial zone of OA cartilage and proceeds
progressively into the middle and deep zones during a
process that occurs over many years7. Recent evidence
indicates that MMP-13 co-localizes with the type II collagen
cleavage products at different stages of progression36.
Since damage in the underlying middle and deep zones is
primarily pericellular, this implies a chondrocyte-mediated
process to which collagenase-3 receptor dysfunction could
contribute.
Although this is the first report correlating dysfunction
of an endocytotic receptor with the arthritic phenotype,
others have described reduced expression of 1 integrin
(adhesion) receptor subunits in OA cartilage54. Chondro-
cytes normally express the 51 integrin (fibronectin recep-
tor55) and engagement of 51 increases collagenase
expression56,57. Accordingly, reduced integrin expression
may stem from a feedback attempt to limit collagenase
synthesis. In contrast, reduced activity of collagenase-3
receptors is likely a primary or exacerbating derangement
in OA. The collagenase-3 receptor is unrelated to members
of the integrin family, since integrin-blocking agents have
no effect on collagenase-3 binding. Moreover, it is unlikely
that a generalized loss of cell-surface components occurs
Fig. 4. MMP binding competition in non-arthritic human chondro-
cytes. Binding assays (with 3 nM 125I collagenase-3) were per-
formed as described above, in the absence or presence of
unlabeled MMPs (300 nM). MMPs-1, -3, and -13 all competed for
binding (P<0.01 by Student’s t-test). Results (pooled from two
experiments) are shown as mean values±S.E.M. for triplicate wells.
Fig. 5. Internalization of collagenase-3 by osteoarthritic and control
human chondrocytes and inhibition by RAP. Experiments were
performed as described in Materials and Methods. Pooled results
from eight experiments (four OA patients, four non-arthritic con-
trols) are shown as mean values±S.E.M.. Differences between OA
and non-arthritic cells and between non-arthritic cells±RAP are
statistically significant (P<0.001 by Student’s t-test).
Fig. 6. Expression of LRP1 in cultured human chondrocytes. Total
RNA was obtained from osteoarthritic and non-arthritic human cells
in primary culture, and RT-PCR was performed using 100 ng of
RNA. Standard cycling conditions were employed for 30 amplifi-
cation cycles for both LRP1 and -actin.
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in OA chondrocytes, as the expression of other integrins
and adhesion molecules is unaltered or increased58.
Surgical implantation of allogeneic chondrocytes into the
damaged joint represents a promising intervention59,60.
However, clinical responses to cartilage transplants will
likely be limited by the primary physiological derangement
that originally led to joint damage. Other chondroprotective
therapies and medications may also be constrained by
disease-promoting factors. If dysfunction of the colla-
genase receptor system indeed relates to the etiology of
OA, efforts to improve receptor function and augment
collagenase clearance will become of paramount interest.
While the findings reported here have direct implications
to arthritis, there are other disease states in which MMPs
are very important, including cancer. For several reasons
[reviewed in reference 61] MMP inhibitors have produced
disappointing results in clinical trials. As Overall and Lopez-
Otin discuss61, more understanding into the mechanisms
regulating MMPs is required to identify strategies for block-
ing the activity of these enzymes in pathological conditions.
The cell-surface receptor binding and internalization pro-
cess we have previously reported in osteoblasts39 and
have again identified in chondrocytes is yet another mech-
anism controlling the levels of MMP-13 and may have
broader implications beyond OA in other diseases involving
MMPs.
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